New Research Finds Vitamin C Could Aid Treatment for Acute Myeloid Leukemia

636081520091215764food supplementscrop.jpg

30 Aug 2016 --- New findings have shown that by supplementing an epigenetic cancer drug called decitabine with vitamin C, it enhanced the drug's ability to impede cancer cell growth and trigger cellular self-destruction in cancer cell lines, prompting the start of a dedicated pilot study.

The pilot clinical trial involving adult patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) at Rigshospitalet in Copenhagen, Denmark, will combine a drug called azacitidine, the standard of care therapy, with vitamin C. 

Many cancer patients are deficient in vitamin C; the proposed approach seeks to correct this deficiency rather than overload patients with the vitamin.

"If the pilot trial is successful, we plan to pursue a larger trial to explore this strategy's potential as a straightforward and cost-effective way to improve the existing therapy for AML and MDS," said Peter Jones, Ph.D., D.Sc., co-senior author of the PNAS study, chief scientific officer at Van Andel Research Institute (VARI) and co-leader of the Van Andel Research Institute-Stand Up To Cancer (VARI-SU2C) Epigenetics Dream Team. 

However, the authors of the study urge patience and caution. Kirsten Grønbæk, M.D., DMSc., chief hematologist and professor at University of Copenhagen’s Rigshospitalet and member of the VARI-SU2C Epigenetics Dream Team, told NutritionInsight: “We will only know if the results of this study will impact actual cancer treatment after a large randomized clinical trial that will run from next year if the pilot data comes out positively. Generally 90 percent of aza patients will have responded after 6 months. Thus I would say we would know whether or not this impacts treatment of MDS/AML within the next 2-3 years.”

The proposed strategy reflects a continuing move toward combination therapies, particularly when it comes to epigenetic approaches, which target the mechanisms that control whether genes are switched "on" or "off."

"This type of combination therapy is promising but more work is needed to determine its safety and efficacy," Grønbæk said. "It is truly exciting to consider that there could be a simple and elegant approach to help patients fight MDS and AML. However, as a physician, I strongly urge patients to wait for the results of the clinical trial and to discuss all dietary and supplemental changes with their doctors."

There are hopes that this study could prompt research into how vitamin C could improve treatments for other types of cancer, too. 

“We investigated cell lines from various cancers and observed similar effects,” explained Grønbæk, “However, hypomethylating drugs are only used in clinical trials in solid tumors. It would be relevant to also investigate the effects of vitamin C supplement in these trials. However, only controlled clinical trials can answer that question.”

For now, the clinical study will look at adult patients with MDS or AML. “We are currently running a pilot trial of 20 patients,” said Grønbæk, “If this comes out positively, we will run a large clinical trial with participating hospitals from US and Nordic countries.”
 
by Hannah Gardiner

Related Articles

Business News

Nutrition 21 launches US media campaign to support Velositol ingredient

11 Dec 2017 --- Nutrition 21, LLC has partnered with NYC-based media relations firm Pitch Publicity and clinical pharmacist James B. LaValle in a national media tour dedicated to educating consumers about the benefits of its proprietary ingredient, Velositol.

Food Ingredients News

Pea stars for Roquette amid alternative protein boom

11 Dec 2017 --- Roquette’s range of pea proteins took a starring role at FiE 2017, and would seem to have a bright future in products promoted by the company. According to the company’s representatives, a key highlight of the company’s newest range of products is around plant-based proteins – many of which are based on pea proteins.

Nutrition & Health News

Soy, cruciferous vegetables linked to fewer breast cancer treatment side effects

11 Dec 2017 --- Consuming soy foods and cruciferous vegetables – such as cabbages, kale, collard greens, bok choy, Brussels sprouts and broccoli – may be associated with a reduction in common side effects of breast cancer treatment in breast cancer survivors, according to a team of scientists led by Georgetown Lombardi Comprehensive Cancer Center. Understanding the role of life style factors with regard to the side effects is important because diet can serve as a modifiable target for possibly reducing symptoms among breast cancer survivors.

Business News

Inflammatory bowel disease rates on the rise outside West, says new study

08 Dec 2017 --- Countries in Africa, Asia, the Middle East and South America have seen a rise in incidence of inflammatory bowel disease as they have become increasingly industrialized and Westernized, a new study has found. The research – a collaboration between the University of Birmingham, UK, the University of Calgary, Canada, and the Chinese University of Hong Kong – is described by the University of Birmingham as the most definitive and comprehensive study of the global epidemiology of inflammatory bowel disease.

Food Ingredients News

NZMP develops innovative fast-digesting milk protein concentrate

08 Dec 2017 --- As part of its ongoing work in the areas of proteins and medical nutrition, Fonterra’s global dairy ingredients B2B brand NZMP has launched a new milk protein concentrate (MPC) coined SureProtein Fast MPC 4868. Compared to standard milk protein offerings, the ingredient is touted as being able to provide muscles with a higher level of amino acids within the first two hours of consumption and is absorbed as quickly as whey protein.

More Articles
URL : http://www.nutritioninsight.com:80/news/new-research-finds-vitamin-c-could-aid-treatment-for-acute-myeloid-leukemia.html